RARECast

RARECast

By RARECastBusiness
Download on the App Store

RARECast episodes

  • Aligning Interests in Rare Disease Partnerships
    Partnering is essential to advancing rare disease therapies, but while researchers, drugmakers, and patient groups share a common desire to bring new treatments to market, differences in how they operate, their culture, and priorities can derail progress. We spoke to Karen Erickson, associate executive director of community engagement at the Alpha-1 Foundation, about the elements of successful partnering, how to align the differing interests of the participants, and how to get everyone to work together to achieve common goals.
    23 min
  • A Veteran Venture Capitalist Discusses Investing in Rare Disease Drug Development
    Art Pappas, a former pharmaceutical executive turned venture capitalist, has spent more than 30 years working for and investing in drug companies. Among the areas he focuses on are rare disease drug developers. We spoke to Pappas about the changing climate for investment in rare disease companies, his thought process in evaluating potential investments, and at what point he considers exit strategies.
    17 min
  • A Patient Group Crafts Guidelines for Working with Pharma
    Patient organizations have long been working with biopharmaceutical companies, but as they have grown more sophisticated about their interactions, they are coming to understand the value in laying out the ground rules for these relationships. Last year, the International Fibrodysplasia Ossificans Progressiva Association, or IFOPA, took the unusual step to craft a set of guidelines for the organization regarding how it engages with the pharmaceutical industry. It made these guidelines public and continues to refine them. We spoke to Betsy Bogard, chair of the IFOPA research committee, about why the organization created the guidelines, how they have affected interactions between the organization and industry, and how other organizations are interested in following suit.
    18 min
  • Bringing Innovation to Business Models for Rare Disease Drug Development
    To bring new therapies to market to treat rare diseases requires more than scientific innovation. Innovation in financing and business models can be critical as well as the need to find ways to cost effectively develop new medicines becomes increasingly important. We spoke to Neil Kumar, CEO of BridgeBio, about his company’s strategy for developing a portfolio of rare disease therapeutics, why the company’s not alone in this effort, and what he’s learned so far through this approach.
    23 min
  • Rethinking Accessibility and Dependency
    A group of twentysomethings backpacking their way through Europe may not sound unusual, but for Kevan Chandler and his friends, their trip in 2016 was by no means a typical backpacking adventure. Chandler, born with the rare neuromuscular condition spinal muscular atrophy, has been wheelchair bound for most of his life. Because the planned trip included several places that were not wheelchair accessible, the friends decided to rig a backpack to carry Chandler and leave the wheelchair at home. We spoke to Chandler about the journey, how it led to the creation of the nonprofit We Carry Kevan, and why he is working to change the way people think about accessibility and dependency.
    19 min
  • How Simon Wheatcroft, Blinded by a Rare Disease, Became an Ultramarathoner
    Simon Wheatcroft lost his ability to see at the age of 17, the result of a rare genetic disorder. After becoming blind, though, Wheatcroft developed a penchant for running. Starting on a soccer field where he ran between goal posts, he graduated to public roadways. Since those early outings where he had sometime painful encounters road signs and other obstacles, Wheatcroft has learned to adapt, use technology and his other senses, and become an ultramarathoner. We spoke to Wheatcroft about the loss of his sight, how he has been able to adapt, and what he’s learned about himself in the process.
    23 min
  • Spark Hoping Its Luxturna Will Become First FDA-Approved Gene Therapy
    Last month, Spark Therapeutics submitted its gene therapy Luxturna, an experimental treatment for a rare inherited disease that causes blindness, to regulators in the United States and Europe. The company also won U.S. Food and Drug Administration designation for the experimental therapy as a treatment for a rare pediatric disease. Luxturna could be the first treatment for inherited retinal disease and the first gene therapy for a genetic disease approved in the United States. We spoke to Paulo Falabella, medical affairs ophthalmic lead for Spark Therapeutics, about Luxturna, what clinical trials to date tell us, and why this represents a significant development for not just Spark, but the entire field of gene therapy.
    18 min
  • What Rare Patient-Investors Can Learn From Venture Capitalists
    Fulcrum Therapeutics is working to develop small molecule drugs to modulate gene activity as a way to treat certain rare diseases. The company, established by the venture capital firm Third Rock Ventures, is initially focusing on Fragile X and a form of muscular dystrophy known as FSHD. We spoke to Walt Kowtoniuk, director of strategy and operations for Fulcrum, about its approach, what he learned working in a venture capital firm, and what advice he would offer rare disease patients turned investors.
    17 min
  • Novel Effort Delivers Failed DMD Drug to Former Clinical Trial Participants
    When BioMarin failed to win U.S. Food and Drug Administration approval for its experimental Duchenne muscular dystrophy drug drisapersen, it decided to its cease development. Though there were concerns about both the safety and efficacy of the drug, there were patients who participated in the clinical trials who felt that they benefitted from it. CureDuchenne established CD Access, a new nonprofit that negotiated a novel agreement with BioMarin to get control of the existing supply of drisapersen, which the nonprofit is distributing to patients in Canada who participated in the clinical trials. We spoke to Debra Miller, CEO and founder of CureDuchenne and CD Access, about the program, how it works, and whether it serves as a model for getting other similar drugs to patients in the future.
    19 min
  • Centogene Seeks to Deliver Diagnoses to Rare Disease Patients Early
    The diagnostic odyssey rare disease patient face can be long and daunting. Centogene is trying to help these patients find answer more quickly through its genetic diagnostics. The company has been focused on getting beyond the noise generated by the rapid increase in the volume of data to get accurate understanding of a patient’s genetics and helping doctors obtain actionable information. Strengthened with a recent $28 million financing, the company is expanding its presence in the United States. We spoke to Arndt Rolfs, CEO of Centogene, about the company’s genetic diagnostic services, its expansion plans, and the competitive advantage it believes it holds in its proprietary data.
    22 min

About RARECast

From the publisher's feed

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.